Immune imbalance of PD-1 and 1 PD-Ls in liver tissues from patients with Hepatitis B-related hepatocellular carcinoma

Yong Liu; Yong Liu; Guiyang Wang; Guiyang Wang; Rui Huang; Rui Huang; Yingying Hao; Yingying Hao; Haiyan Chang; Haiyan Chang; Chen Tian; Chen Tian; Yang Li; Yang Li; Xiang-An Zhao; Xiang-An Zhao; Juan Xia; Juan Xia; Yuxin Chen; Yuxin Chen; Chao Wu; Chao Wu

doi:10.18632/oncotarget.24206

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 01/12/2018.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

Immune imbalance of PD-1 and 1 PD-Ls in liver tissues from patients with Hepatitis B-related hepatocellular carcinoma

Yong Liu _, Yong Liu, Guiyang Wang, Guiyang Wang, Rui Huang, Rui Huang, Yingying Hao, Yingying Hao, Haiyan Chang, Haiyan Chang, Chen Tian, Chen Tian, Yang Li, Yang Li, Xiang-An Zhao, Xiang-An Zhao, Juan Xia, Juan Xia, Yuxin Chen, Yuxin Chen, Chao Wu and Chao Wu _

Yong Liu1,2, Guiyang Wang3, Rui Huang3, Yingying Hao4, Haiyan Chang3, Chen Tian3, Yang Li3, Xiang-An Zhao3, Juan Xia3, Yuxin Chen3,5 and Chao Wu3

1 Department of Experimental Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China

2 Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China

3 Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China

4 Department of Intensive Care Units, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China

5 Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China

Correspondence to:

Chao Wu, email: [email protected]

Yuxin Chen, email: [email protected]

Keywords: PD-1; PD-L1; PD-L2; microenvironment; hepatitis B-related hepatocellular carcinoma

Received: October 27, 2017 Accepted: December 05, 2017 Epub: January 12, 2018

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24206

Publication Alerts

Withdrawal Notice

Research Papers:

Immune imbalance of PD-1 and 1 PD-Ls in liver tissues from patients with Hepatitis B-related hepatocellular carcinoma